Melanoma NOS1 expression promotes dysfunctional IFN signaling.

In multiple forms of cancer, constitutive activation of type I IFN signaling is a critical consequence of immune surveillance against cancer; however, PBMCs isolated from cancer patients exhibit depressed STAT1 phosphorylation in response to IFN-α, suggesting IFN signaling dysfunction. Here, we demonstrated in a coculture system that melanoma cells differentially impairs the IFN-α response in PBMCs and that the inhibitory potential of a particular melanoma cell correlates with NOS1 expression. Comparison of gene transcription and array comparative genomic hybridization (aCGH) between melanoma cells from different patients indicated that suppression of IFN-α signaling correlates with an amplification of the NOS1 locus within segment 12q22-24. Evaluation of NOS1 levels in melanomas and IFN responsiveness of purified PBMCs from patients indicated a negative correlation between NOS1 expression in melanomas and the responsiveness of PBMCs to IFN-α. Furthermore, in an explorative study, NOS1 expression in melanoma metastases was negatively associated with patient response to adoptive T cell therapy. This study provides a link between cancer cell phenotype and IFN signal dysfunction in circulating immune cells.

[1]  B. Schilling,et al.  Induced and natural regulatory T cells in human cancer , 2012, Expert opinion on biological therapy.

[2]  F. Marincola,et al.  A genetic inference on cancer immune responsiveness , 2012, Oncoimmunology.

[3]  F. Marincola,et al.  Reflections upon human cancer immune responsiveness to T cell-based therapy , 2012, Cancer Immunology, Immunotherapy.

[4]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[5]  F. Marincola,et al.  The stable traits of melanoma genetics: an alternate approach to target discovery , 2012, BMC Genomics.

[6]  L. Rivoltini,et al.  Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients , 2012, Cancer Immunology, Immunotherapy.

[7]  F. Marincola,et al.  The immune score as a new possible approach for the classification of cancer , 2012, Journal of Translational Medicine.

[8]  S. Ambs,et al.  Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. , 2011, Trends in pharmacological sciences.

[9]  F. Marincola,et al.  Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma , 2011, Clinical Cancer Research.

[10]  F. Marincola,et al.  An immunologic portrait of cancer , 2011, Journal of Translational Medicine.

[11]  J. Kirkwood,et al.  Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients , 2011, Journal of Translational Medicine.

[12]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[13]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[14]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[15]  S. Rosenberg,et al.  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma , 2010, Clinical Cancer Research.

[16]  F. Marincola,et al.  Genomic scale analysis of racial impact on response to IFN-α , 2009, Proceedings of the National Academy of Sciences.

[17]  A. Anichini,et al.  Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage , 2009, Clinical Cancer Research.

[18]  Albert Koong,et al.  Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.

[19]  S. Fais,et al.  More insights into the immunosuppressive potential of tumor exosomes , 2008, Journal of Translational Medicine.

[20]  M. Radmacher,et al.  Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α , 2008, Clinical Cancer Research.

[21]  F. Marincola,et al.  The immunologic constant of rejection. , 2008, Trends in immunology.

[22]  M. Neurath,et al.  Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. , 2008, Current drug targets.

[23]  F. Marincola,et al.  Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. , 2008, Cancer research.

[24]  G. Lesinski,et al.  Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-α Compared with Immune Effector Cells , 2007, Clinical Cancer Research.

[25]  M. Ringnér,et al.  Genomic profiling of malignant melanoma using tiling-resolution arrayCGH , 2007, Oncogene.

[26]  Serban Nacu,et al.  Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma , 2007, PLoS medicine.

[27]  D. Jukic,et al.  Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b , 2007, Clinical Cancer Research.

[28]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[29]  L. Ivashkiv,et al.  Role of STAT3 in Type I Interferon Responses , 2006, Journal of Biological Chemistry.

[30]  T. Whiteside,et al.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.

[31]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[32]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[33]  G. Lesinski,et al.  Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. , 2004, Journal of the National Cancer Institute.

[34]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[35]  Hua Yu,et al.  A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.

[36]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[37]  F. Marincola,et al.  Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model , 1999, International journal of cancer.

[38]  R. Jove,et al.  Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. , 1997, Cancer research.

[39]  D. Longo,et al.  Alterations in T cell receptor and signal transduction molecules in melanoma patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Trent,et al.  Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. , 1995, Cancer genetics and cytogenetics.

[41]  O. Lloyd,et al.  Management of Malignant Melanoma [Abridged] , 1969 .

[42]  A. Cochran.  Histology and prognosis in malignant melanoma , 1969, The Journal of pathology.